As for prostate cancer, the addition of the genes included in this review to BRCA1 and BRCA2 more than doubles the mutational burden in both germline and in somatic sample PVs (8.6% to 20.7% and 15.2% to 36.9%). The gene discussed is BRCA1; the disease is Familial prostate cancer.